{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:10:17Z","timestamp":1790251817843,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K02315"],"award-info":[{"award-number":["JP24K02315"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K23968"],"award-info":[{"award-number":["25K23968"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K19190"],"award-info":[{"award-number":["24K19190"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15314"],"award-info":[{"award-number":["23K15314"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H05873"],"award-info":[{"award-number":["JP20H05873"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008886","name":"Princess Takamatsu Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22ama121037 and JP243fa627005"],"award-info":[{"award-number":["JP22ama121037 and JP243fa627005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA259188"],"award-info":[{"award-number":["R01 CA259188"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["ACS RSG-23-722314"],"award-info":[{"award-number":["ACS RSG-23-722314"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03055-5","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T07:23:17Z","timestamp":1783927397000},"page":"2133-2142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7146-2742","authenticated-orcid":false,"given":"Yuto","family":"Mori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-5664","authenticated-orcid":false,"given":"Keito","family":"Suto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keito","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2731-6091","authenticated-orcid":false,"given":"Masahiro","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-5692","authenticated-orcid":false,"given":"Hiroo","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiyuki","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Otsuguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Maenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9948-8696","authenticated-orcid":false,"given":"Yibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8602-6054","authenticated-orcid":false,"given":"Masao","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"3055_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D International TCLP International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"3055_CR2","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1182\/blood-2014-07-584953","volume":"124","author":"C Bossard","year":"2014","unstructured":"Bossard C, Dobay MP, Parrens M, Lamant L, Missiaglia E, Haioun C, et al. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014;124:2983\u20136.","journal-title":"Blood"},{"key":"3055_CR3","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","volume":"102","author":"JA Francisco","year":"2003","unstructured":"Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458\u201365.","journal-title":"Blood"},{"key":"3055_CR4","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Trumper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288\u201398.","journal-title":"Ann Oncol"},{"key":"3055_CR5","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1038\/s41375-025-02811-3","volume":"39","author":"K Suto","year":"2025","unstructured":"Suto K, Takei N, Yokoyama K, Chiba M, Ishio T, Maeda M, et al. Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma. Leukemia. 2025;39:3061.","journal-title":"Leukemia"},{"key":"3055_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41580-023-00593-z","volume":"24","author":"AD McAinsh","year":"2023","unstructured":"McAinsh AD, Kops G. Principles and dynamics of spindle assembly checkpoint signalling. Nat Rev Mol Cell Biol. 2023;24:543\u201359.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3055_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2018.06.014","volume":"34","author":"M Nakagawa","year":"2018","unstructured":"Nakagawa M, Shaffer AL 3rd, Ceribelli M, Zhang M, Wright G, et al. Targeting the HTLV-I-Regulated BATF3\/IRF4 Transcriptional Network in Adult T Cell Leukemia\/Lymphoma. Cancer Cell. 2018;34:286\u2013297.e210.","journal-title":"Cancer Cell"},{"key":"3055_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1182\/blood.2021012734","volume":"139","author":"T Ishio","year":"2022","unstructured":"Ishio T, Kumar S, Shimono J, Daenthanasanmak A, Dubois S, Lin Y, et al. Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in adult T-cell leukemia\/lymphoma. Blood. 2022;139:1541\u201356.","journal-title":"Blood"},{"key":"3055_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"3055_CR10","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","volume":"15","author":"D Rudolph","year":"2009","unstructured":"Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009;15:3094\u2013102.","journal-title":"Clin Cancer Res"},{"key":"3055_CR11","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1182\/blood-2014-03-560557","volume":"124","author":"H Dohner","year":"2014","unstructured":"Dohner H, Lubbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, et al. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. Blood. 2014;124:1426\u201333.","journal-title":"Blood"},{"key":"3055_CR12","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1097\/HS9.0000000000000617","volume":"5","author":"H Dohner","year":"2021","unstructured":"Dohner H, Symeonidis A, Deeren D, Demeter J, Sanz MA, Anagnostopoulos A, et al. Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. Hemasphere. 2021;5:e617.","journal-title":"Hemasphere"},{"key":"3055_CR13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1200\/JCO.2015.62.1474","volume":"34","author":"E Pujade-Lauraine","year":"2016","unstructured":"Pujade-Lauraine E, Selle F, Weber B, Ray-Coquard IL, Vergote I, Sufliarsky J, et al. Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l\u2019Etude des Cancers de l\u2019Ovaire Study. J Clin Oncol. 2016;34:706\u201313.","journal-title":"J Clin Oncol"},{"key":"3055_CR14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cllc.2015.05.010","volume":"16","author":"PM Ellis","year":"2015","unstructured":"Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, et al. A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015;16:457\u201365.","journal-title":"Clin Lung Cancer"},{"key":"3055_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/cncr.28519","volume":"120","author":"WM Stadler","year":"2014","unstructured":"Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, et al. An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2014;120:976\u201382.","journal-title":"Cancer"},{"key":"3055_CR16","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s44318-025-00400-9","volume":"44","author":"M Gobran","year":"2025","unstructured":"Gobran M, Politi AZ, Welp L, Jakobi J, Urlaub H, Lenart P. PLK1 inhibition delays mitotic entry revealing changes to the phosphoproteome of mammalian cells early in division. EMBO J. 2025;44:1891\u2013920.","journal-title":"EMBO J"},{"key":"3055_CR17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486\u2013541.","journal-title":"Cell Death Differ"},{"key":"3055_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrm3115","volume":"12","author":"I Vitale","year":"2011","unstructured":"Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 2011;12:385\u201392.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3055_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.tibs.2025.02.005","volume":"50","author":"VM Bolanos-Garcia","year":"2025","unstructured":"Bolanos-Garcia VM. Mps1 kinase functions in mitotic spindle assembly and error correction. Trends Biochem Sci. 2025;50:438\u201353.","journal-title":"Trends Biochem Sci"},{"key":"3055_CR20","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1182\/bloodadvances.2023009953","volume":"7","author":"WT Johnson","year":"2023","unstructured":"Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, et al. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood Adv. 2023;7:5172\u201386.","journal-title":"Blood Adv"},{"key":"3055_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.17749","volume":"195","author":"Y Sakamoto","year":"2021","unstructured":"Sakamoto Y, Ishida T, Masaki A, Murase T, Takeshita M, Muto R, et al. Clinical significance of TP53 mutations in adult T-cell leukemia\/lymphoma. Br J Haematol. 2021;195:571\u201384.","journal-title":"Br J Haematol"},{"key":"3055_CR22","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/s41375-025-02631-5","volume":"39","author":"Y Ito","year":"2025","unstructured":"Ito Y, Shimono J, Kawamoto K, Hatanaka KC, Kogure Y, Tabata M, et al. TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma. Leukemia. 2025;39:1723\u201334.","journal-title":"Leukemia"},{"key":"3055_CR23","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-10-2946","volume":"17","author":"D Olmos","year":"2011","unstructured":"Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res. 2011;17:3420\u201330.","journal-title":"Clin Cancer Res"},{"key":"3055_CR24","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1200\/JCO-24-01266","volume":"43","author":"DH Ahn","year":"2025","unstructured":"Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, et al. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. J Clin Oncol. 2025;43:840\u201351.","journal-title":"J Clin Oncol"},{"key":"3055_CR25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1158\/1535-7163.MCT-11-0765","volume":"11","author":"B Valsasina","year":"2012","unstructured":"Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, et al. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012;11:1006\u201316.","journal-title":"Mol Cancer Ther"},{"key":"3055_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114747","volume":"193","author":"S Iliaki","year":"2021","unstructured":"Iliaki S, Beyaert R, Afonina IS. Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem Pharmacol. 2021;193:114747.","journal-title":"Biochem Pharmacol"},{"key":"3055_CR27","doi-asserted-by":"publisher","first-page":"5272","DOI":"10.1182\/bloodadvances.2023010254","volume":"7","author":"PL Zinzani","year":"2023","unstructured":"Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, et al. Nivolumab combined with brentuximab vedotin for R\/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv. 2023;7:5272\u201380.","journal-title":"Blood Adv"},{"key":"3055_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1182\/blood.2020009178","volume":"138","author":"RH Advani","year":"2021","unstructured":"Advani RH, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138:427\u201338.","journal-title":"Blood"},{"key":"3055_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00280-023-04609-5","volume":"93","author":"Y Tonozuka","year":"2024","unstructured":"Tonozuka Y, Tanaka H, Nomura K, Sakaguchi K, Soeda J, Kakimoto Y. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis. Cancer Chemother Pharmacol. 2024;93:137\u201349.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3055_CR30","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","volume":"37","author":"O Saatci","year":"2018","unstructured":"Saatci O, Borgoni S, Akbulut O, Durmus S, Raza U, Eyupoglu E, et al. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer. Oncogene. 2018;37:2251\u201369.","journal-title":"Oncogene"},{"key":"3055_CR31","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1038\/cdd.2015.59","volume":"22","author":"M Hugle","year":"2015","unstructured":"Hugle M, Belz K, Fulda S. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs. Cell Death Differ. 2015;22:1946\u201356.","journal-title":"Cell Death Differ"},{"key":"3055_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.canlet.2015.04.011","volume":"365","author":"A Stehle","year":"2015","unstructured":"Stehle A, Hugle M, Fulda S. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma. Cancer Lett. 2015;365:37\u201346.","journal-title":"Cancer Lett"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03055-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03055-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:13Z","timestamp":1790250193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03055-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3055"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03055-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. A human biopsy sample was obtained after written informed consent in accordance with the Declaration of Helsinki under a protocol approved by the Institutional Review Board of Hokkaido University (approval no. 024-0215). Animal experiments were approved by the Institutional Animal Care and Use Committee of Hokkaido University (approval nos. 23-0109, 24-0126, and 24-0128).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}